The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...

NTDs, a group of 21 debilitating infectious diseases, affect over 1 billion people globally, causing significant morbidity, disability, and death. These diseases, including visceral leishmaniasis (VL) ...

The company expects 2025 adjusted profit to be in the range of $8.15 to $8.35 per share, compared with the average of ...

US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials ...

Flies circulating in hospital wards may pose a threat to vulnerable patients by spreading bacteria that are resistant to ...